Medical/Pharmaceuticals

HEALTH SUMMIT ASIA 2026 CONFIRMS OVER 30 GLOBAL HEALTHCARE LEADERS FOR CONFERENCE

KUALA LUMPUR, Malaysia, March 26, 2026 /PRNewswire/ -- Health Summit Asia (HSA) 2026 has confirmed more than 30 distinguished speakers from across the globe, underscoring the event's scale and significance for Malaysia and the wider region. Their calibre spans public health, cancer research, AI i...

2026-03-26 14:30 5045

Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights * KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-lin...

2026-03-26 13:13 7916

Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction

TOKYO, March 26, 2026 /PRNewswire/ -- NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of S...

2026-03-26 10:00 5725

XtalPi Holdings Announces Full Year 2025 Annual Results

HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. * Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making th...

2026-03-25 22:27 12693

Heidi Receives Frost & Sullivan's 2026 North American Technology Innovation Leadership Recognition for Excellence in Artificial Intelligence Medical Scribe Innovation

The recognition highlights Heidi's leadership in clinical AI innovation, market impact, and customer-centric technology design. SAN ANTONIO, March 25, 2026 /PRNewswire/ -- Frost & Sullivan

2026-03-25 21:00 4133

Axtria Recognized as Frost & Sullivan's 2025 Global Company of the Year in Pharma Commercial Solutions

Honored for AI-Driven Innovation, Measurable Client Impact, and Industry-Leading Commercialization Excellence BERKELEY HEIGHTS, N.J., March 25, 2026 /PRNewswire/ -- Axtria Inc. ...

2026-03-25 20:33 4233

Waterdrop Q4 and FY2025 Financial Results: Q4 operating revenue rises 105.5% YoY, and declared a cash dividend

BEIJING, March 25, 2026 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended December 31, 2025 and a cash dividen...

2026-03-25 20:24 6012

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today * The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal ...

2026-03-25 19:00 4791

ENNOVI Secures German Patent Approval for Adhesive-Free Lamination in Battery Cell Contacting Systems

Offering a new, validated CCS design pathway, reducing uncertainty for cautious battery engineers NECKARSULM, Germany, March 25, 2026 /PRNewswire/ -- ENNOVI

2026-03-25 19:00 5098

Why Chronic Eczema Can Last for Decades, and What a Recent Case Is Revealing

Tangs Clinical TCM Highlights Why Chronic Eczema Can Persist for Decades SINGAPORE, March 25, 2026 /PRNewswire/ -- A recent patient case managed by Tangs Clinical TCM has shed light on why chronic eczema can last for years, and how long-term, structured management may influence symptom patterns o...

2026-03-25 15:40 2740

Fujitsu and The University of Osaka develop new technologies for chemical material energy calculations on early-FTQC quantum computers

Contributing to the early application of quantum computers in drug discovery and new material development  TOKYO, March 25, 2026 /PRNewswire/ -- Fujitsu Limited and the Center for Quantum Information and Quantum Biology at The University of Osaka today announced the development of a new technolo...

2026-03-25 13:29 5754

Open-Sourcing to Empower, AI to Lead Medicine: "SurgMotion", the Best-in-class Surgical Video Foundation Model, Officially Launched

HONG KONG, March 25, 2026 /PRNewswire/ -- On 24 March, the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), and the Chinese Academy of Sciences unveiled "SurgMotion" — a surgical video foundation model — at the Hong Kong Science and Tech...

2026-03-25 11:00 7154

BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing

* International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals * Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- BIOTRONIK today announced the initiation of its g...

2026-03-24 22:06 3417

Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship

New findings highlight rising—yet hidden—patient use of AI and surprisingly optimistic providers, pointing to an emerging "triangle of care" NEW YORK, March 24, 2026 /PRNewswire/ -- Zocdoc, the healthcare access infrastructure connecting patients to great care, today releasedThe AI-Informed Pati...

2026-03-24 21:00 3222

ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care

* Expanded treatment and visualization capabilities within posterior care workflows: ICGA for ZEISS CLARUS 700 offers FA + ICG simultaneous capture to help support clinical assessment and streamline the diagnostic process; ZEISS VISULAS green, now available with ZEISS SLT, offers dependable ret...

2026-03-24 21:00 4444

Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials

New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challen...

2026-03-24 20:00 4367

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today ann...

2026-03-24 20:00 3365

Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC

CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...

2026-03-24 17:24 5204

DualityBio (9606.HK) Announces 2025 Annual Results

HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...

2026-03-24 15:55 5851

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study ev...

2026-03-24 11:32 4601
1 ... 34353637383940 ... 383